Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes : systematic review and economic evaluation

Tools
- Tools
+ Tools

Johnston, Rhona, Uthman, Olalekan A., Cummins, Ewen, Clar, Christine, Royle, Pamela, Colquitt, Jill, Tan, Bee K., Clegg, Andrew, Shantikumar, Saran, Court, Rachel A., O'Hare, J. Paul, McGrane, David, Holt, Tim and Waugh, Norman (2017) Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes : systematic review and economic evaluation. Health Technology Assessment, 21 (2). pp. 1-218. doi:10.3310/hta21020

[img] PDF
WRAP_3009557.pdf - Published Version - Requires a PDF viewer.

Download (6Mb)
Official URL: http://dx.doi.org/10.3310/hta21020

Request Changes to record.

Abstract

Background

Most people with type 2 diabetes are overweight, so initial treatment is aimed at reducing weight and increasing physical activity. Even modest weight loss can improve control of blood glucose. If drug treatment is necessary, the drug of first choice is metformin. However, some people cannot tolerate metformin, which causes diarrhoea in about 10%, and it cannot be used in people with renal impairment. This review appraises three of the newest class of drugs for monotherapy when metformin cannot be used, the sodium–glucose co-transporter 2 (SGLT2) inhibitors.

Objective

To review the clinical effectiveness and cost-effectiveness of dapagliflozin (Farxiga, Bristol-Myers Squibb, Luton, UK), canagliflozin (Invokana, Janssen, High Wycombe, UK) and empagliflozin (Jardiance, Merck & Co., Darmstadt, Germany), in monotherapy in people who cannot take metformin.

Sources

MEDLINE (1946 to February 2015) and EMBASE (1974 to February 2015) for randomised controlled trials lasting 24 weeks or more. For adverse events, a wider range of studies was used. Three manufacturers provided submissions.

Methods

Systematic review and economic evaluation. A network meta-analysis was carried out involving the three SGLT2 inhibitors and key comparators. Critical appraisal of submissions from three manufacturers.

Results

We included three trials of dapagliflozin and two each for canagliflozin and empagliflozin. The trials were of good quality. The canagliflozin and dapagliflozin trials compared them with placebo, but the two empagliflozin trials included active comparators. All three drugs were shown to be effective in improving glycaemic control, promoting weight loss and lowering blood pressure (BP

Item Type: Journal Article
Subjects: R Medicine > RC Internal medicine
Divisions: Faculty of Medicine > Warwick Medical School > Health Sciences
Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Non-insulin-dependent diabetes -- Treatment -- Cost effectiveness, Systematic reviews (Medical research)
Journal or Publication Title: Health Technology Assessment
Publisher: NIHR Health Technology Assessment programme
ISSN: 1366-5278
Official Date: January 2017
Dates:
DateEvent
January 2017Published
20 January 2017Accepted
Volume: 21
Number: 2
Page Range: pp. 1-218
DOI: 10.3310/hta21020
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access
Funder: National Institute for Health Research (Great Britain). Technology Assessment Programme (NIHR TAP)

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us